SCHEMBL79142

SCHEMBL79142

CN1CCN(C(=O)c2cnc(C(C(N)=O)=C3Nc4ccccc4S3)nc2C(F)(F)F)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CXCR4 P61073 1/20 0.36
SCD O00767 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HRH4 Q9H3N8 4/20 0.34
GAA P10253 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
HIF1A Q16665 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34
KMT2A Q03164 1/20 0.34
HTT P42858 1/20 0.34
HSD17B10 Q99714 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRL1 P41146 1/20 0.34
SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL79141 1.00 ALDH1A1 (0.36) ALDH1A1HPGDKDM4ECXCR4SCD
Hydrochloric Acid SCHEMBL77231 0.99 ALDH1A1 (0.36) ALDH1A1HPGDKDM4ECXCR4SCD
Hydrochloric Acid SCHEMBL77232 0.99 ALDH1A1 (0.36) ALDH1A1HPGDKDM4ECXCR4SCD
SCHEMBL77884 0.83 GAA (0.37) ALDH1A1GAASMN1; SMN2NPC1RAB9A
SCHEMBL77885 0.83 GAA (0.37) ALDH1A1GAASMN1; SMN2NPC1RAB9A
SCHEMBL86006 0.82 MAPT (0.40) ALDH1A1KDM4EGAAKMT2A
SCHEMBL86094 0.78 PDE4B (0.44) KMT2A
SCHEMBL86107 0.76 BCL3 (0.42) ALDH1A1HPGDKDM4EGAASMN1; SMN2
SCHEMBL10105401 0.74 HSD17B10 (0.34) ALDH1A1HPGDKDM4EGAAKMT2A
SCHEMBL85792 0.73 KCNH2 (0.41) HPGDL3MBTL1HRH4CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129396-B2 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. (US) 2012-03-06 US disclosed
US-20100081653-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081653-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors MAP3K2, MAP4K2, MAP3K12 ALDH1A1 1651/4885HPGD 2547/4885KDM4E 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.